Home Tags ASG-22ME

Tag: ASG-22ME

Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D...

In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology,...

Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...

Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...

Promising Phase I Data for Enfortumab Vedotin (ASG-22ME) and ASG-15ME in...

The annual congress of the European Society of Medical Oncology (ESMO), this year held in Copenhagen, Denmark (October 7 - 11, 2016) is the premier...

Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...

With two approved antibody-drug conjugates and a large number of  ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

X